German researchers find reason for remdesivir’s inefficiency
German Researchers have unraveled how remdesivir interferes with the viral RNA polymerase and why it does not block SARS-CoV-2 completely.
ADVERTISEMENT
About Thomas Gabrielczyk
This author has not written his bio yet.
But we are proud to say that Thomas Gabrielczyk contributed 2066 entries already.
Entries by Thomas Gabrielczyk
LSP reports first closing of dementia fund
European life sciences investors LSP has closed a new fund to fight dementia at €50m.
Valneva in talks with EU about 60 million vaccine doses
French Valneva SE announced it is in advanced discussions with the European Commission (EC) for the supply of up to 60 million doses of its COVID-19 vaccine, VLA2001.
Immunocore bags US$75m in Series C round
Immuno-oncology specialist Immunocore plc announced the completion of a $75m Series C private financing round.
EU approves second COVID-19 vaccine
Following a recommendation by the European Medicines Agency (EMA), the European Commission has approved a second vaccine against the novel coronavirus SARS-CoV-2.
Angelini Pharma to take over Arvelle Therapeutics
Italian Angelini Pharma and Swiss CNS disease specialist Arvelle Therapeutics have entered into a definitive merger agreement.
COVID-19 test gives results within minutes
University of Birmingham researchers have invented a COVID-19 RNA test that reduces testing time from 30 minutes to under five, and delivers accurate results.
Merry Christmas and a Happy New Year
Dear readers,
We wish all visitors to our news page a peaceful and healthy New Year and a successful start to the New Year. Stay healthy! We will be back with the latest news from 4 January.
Best regards
Your editorial team of European Biotechnology Magazine
EMA greenlights BioNtech’s COVID-19 vaccine
Following a rapid FDA approval, the European drug authority EMA has recommended to conditionally approve BioNTech’s mRNA vaccine BNT162b2 in the EU.
European Circular Bioeconomy Fund growing
Only two and a half months after its launch, the EU bioecocomy venture capital fund ECBF has doubled the volume of its first closing.